Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic
Open accessPublished version of a preprint
The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Attack rate in Manaus: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) incidence peaked in Manaus, Brazil, in May 2020 with a devastating toll on the city's inhabitants, leaving its health services shattered and cemeteries overwhelmed. Buss et al. collected data from blood donors from Manaus and São Paulo, noted when transmission began to fall, and estimated the final attack rates in October 2020 (see the Perspective by Sridhar and Gurdasani). Heterogeneities in immune protection, population structure, poverty, modes of public transport, and uneven adoption of nonpharmaceutical interventions mean that despite a high attack rate, herd immunity may not have been achieved. This unfortunate city has become a sentinel for how natural population immunity could influence future transmission. Events in Manaus reveal what tragedy and harm to society can unfold if this virus is left to run its course. Science , this issue p. 288 ; see also p. 230
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“epidemiological studies suggest that, even in communities with high infection rates, herd immunity through natural infection may not have been achieved, and these studies raise the possibility that a combination of waning immunity and viral antigenic variation may allow for continued circulation of the virus11,12.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Manaus experienced a strong wave of SARS-CoV-2 infection in April and May of 2020, which might have been expected to provide some level of protection or herd immunity in the exposed population. However, despite a low level of transmission from June to December 2020, a resurgence of infection was observed in early 2021 (refs11,57).”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This contrasts with the seroepidemiological evidence for ongoing spread of infection in a highly exposed population in Manaus, which suggests that there may be susceptibility to reinfection after 6–8 months11,12.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As the Gamma variant was associated with a surge of infections in a region of Brazil estimated to have achieved a high infection rate, it is suspected of being able to infect and cause illness in persons previously infected with other variants 19,29,30 .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [29]
Experimental — accuracy not yet measuredIn the citing paper
“Several studies have estimated cumulative infections in select countries at specific points in time.6, 7, 8, 9”
From Estimating global, regional, and national daily and cumulative infections with SARS-CoV-2 through Nov 14, 2021: a statistical analysis (2022) · cites this paper as [6]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimates of the severity of coronavirus disease 2019: a model-based analysis
Verity, R., Okell, L. C., Dorigatti, I., Winskill, P., Whittaker, C., Imai, N., Cuomo-Dannenburg, G., Thompson, H., Walker, P. G. T., Fu, H., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30243-7 · Cited by 3,660
Self-citationFerguson, N. M., Laydon, D. J., Nedjati-Gilani, G. L., Imai, N., Ainslie, K. E. C., Baguelin, M., Bhatia, S., Boonyasiri, A., Cucunubá, Z. M., Cuomo-Dannenburg, G., et al. (2020) · Spiral (Imperial College London) · doi:10.25561/77482 · Cited by 3,281
Self-citationClinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
Mizumoto, K., Kagaya, K., Zarebski, A., & Chowell, G. (2020) · Eurosurveillance · doi:10.2807/1560-7917.es.2020.25.10.2000180 · Cited by 2,276
Empirical Likelihood and General Estimating Equations
Qin, J., & Lawless, J. (1994) · The Annals of Statistics · doi:10.1214/aos/1176325370 · Cited by 1,715
Pollán, M., Pérez-Gómez, B., Pastor-Barriuso, R., Oteo, J., Hernán, M. A., Pérez-Olmeda, M., Sanmartín, J. L., Fernández-García, A., Cruz, I., Fernández de Larrea, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31483-5 · Cited by 1,639
"Herd Immunity": A Rough Guide
Fine, P., Eames, K., & Heymann, D. L. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir007 · Cited by 1,247
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195
ESTIMATING PREVALENCE FROM THE RESULTS OF A SCREENING TEST
ROGAN, W. J., & GLADEN, B. (1978) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112510 · Cited by 1,001
Stringhini, S., Wisniak, A., Piumatti, G., Azman, A. S., Lauer, S. A., Baysson, H., De Ridder, D., Petrovic, D., Schrempft, S., Marcus, K., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31304-0 · Cited by 990
Research works printed but not linked: 1
- 10.1186/1742-7622-9-9 · DOI
Cited by
Items 401–486 of 486
Genomics and epidemiology of SARS-CoV-2 lineage
Sukegawa, S., & Takeuchi, H. (2021) · Uirusu · doi:10.2222/jsv.71.19 · Cited by 1
COVID-19 PANDEMICS: HOW FAR ARE WE FROM HERD IMMUNITY?Preprint
Hernández-Suárez, C., Murillo‐Zamora, E., & Espinoza‐Gómez, F. (2020) · medRxiv · doi:10.1101/2020.12.19.20248571 · Cited by 1
“For instance, if we believe 15% of deaths was unrecorded in Manaus, p=0.85 and this would increase our previous estimate of 63% infected to 74%, much closer to the estimated value in October [27].”
BackgroundResultInfluentialChisolm, T., Walker, J. P., Leys, Y. E., Butterfield, T. R., Medley, C., Thompson, T. K., Reynolds-Campbell, G., Mulder, W. H., Mitchell, M. C., & Anzinger, J. J. (2021) · medRxiv · doi:10.1101/2021.02.08.21251367 · Cited by 1
SARS-CoV-2 genome sequencing with Oxford Nanopore Technology and Rapid PCR Barcoding in BoliviaPreprint
Rollano-Peñaloza, O. M., Barrera, C. D., & Michel, A. V. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.06.451357 · Cited by 1
da Mata, M. M., Neves, J. A., & de Medeiros, M. A. T. (2021) · Research Square · doi:10.21203/rs.3.rs-634658/v1 · Cited by 1
Coccia, M. (2022) · Preprints.org · doi:10.20944/preprints202211.0148.v1 · Cited by 1
Coccia, M. (2023) · Qeios · doi:10.32388/vzsyam
Torgerson, P. R., Hartnack, S., Rasmussen, P., Lewis, F. I., O’Donnell, P., & Langton, T. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.09.18.613634 · Cited by 1
“Such adjustments are increasingly used, such as modelling the covid-19 pandemic (10). bTB should be no exception.”
MethodCOVID-19 case management: The policy model in Morocco contextPreprint
Bennis, I. (2020) · medRxiv · doi:10.1101/2020.11.07.20227603 · Cited by 1
Wodarz, D., Komarova, N. L., & Schang, L. M. (2020) · medRxiv · doi:10.1101/2020.11.23.20237172
Neutralising antibodies and virus isolation: The keys to control covert COVID-19 spread?
Morand, G. B. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100027
“Recent reports from nonmitigated environment have however shown a three quarter attack rate from SARS-CoV-2 [2], meanwhile European serologic studies indicated after the first wave a seroprevalence of ~10 15% [3], underlying the yet long way to go to control the disease.”
InfluentialVaccination Uncertainties and COVID-19 Prospects in 2021
Wu, P., Cowling, B. J., & Leung, G. M. (2021) · China CDC Weekly · doi:10.46234/ccdcw2021.044
Hatchett, R. J., & Weekly, C. C. (2021) · China CDC Weekly · doi:10.46234/ccdcw2021.043
Ku, M.-W., Authié, P., Bourgine, M., Anna, F., Noirat, A., Moncoq, F., Vesin, B., Névo, F., Lopez, J., Souque, P., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-415309/v1 · Cited by 1
“A codon-optimized prefusion S sequence (1-1262) (Table S2) was amplified from pMK-RQ_S-2019304 nCoV and inserted into pFlap by restriction/ligation between BamHI and XhoI sites, between the native 305 human ieCMV promoter and a mutated Woodchuck Posttranscriptional Regulatory Element (WPRE) 306”
MethodPékpé, K. M., Zitouni, D., Gasso, G., Dhifli, W., & Guinhouya, B. C. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2106.11918
Sim, M., Cockcroft, C., Darby, D., Ellis, C. R., Heaps, A. G., Scargill, J., & Garcez, T. P. (2021) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/00045632211030957
“This relative decrease seen on the Abbott platform has been described in other longitudinal cohorts.(5,6) Differences in assay format and design beyond the main assay target may account for this, as the Roche nucleocapsid assay did not show the same deterioration.”
ResultCOVID-19 no Brasil: “cobertor curto”
da Silva, R. M. (2021) · Conexão Ciência (Online) · doi:10.24862/cco.v16i1.1476
Goldenbogen, B., Adler, S. O., Bodeit, O., Wodke, J. A. H., Escalera‐Fanjul, X., Korman, A., Krantz, M., Bonn, L., Torres, R. M., Haffner, J., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-716282/v1
Mateos, S. D. O. G. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2021.tde-19082021-131904
Xavier, D. R., Silva, E. L. E., Lara, F. A., Silva, G. R. R. E., de Oliveira, M. F., Gurgel, H., & Barcellos, C. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3949486
Further Discussion on the Attack Rate and Reinfections in Manaus, BrazilPreprint
He, D., Artzy‐Randrup, Y., Musa, S. S., Gräf, T., Hallal, P. C., Naveca, F. G., & Stone, L. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3929140
Endo, P. T., Oliveira, G. A. D., Lima, L. C. D., da Silva, I. M. D., & Lynn, G. L. A. T. (2021) · IADIS International Conference on e-Society (ES) · doi:10.33965/es2021_202101l003
“5 fold excess morality by early May; by June, 44% of the population in Manaus had detectable COVID-19 antibodies (Orellana et al. 2020; Buss et al. 2020).”
BackgroundInfluentialLucinde, R. K., Mugo, D., Bottomley, C., Karani, A., Gardiner, E., Aziza, R., Gitonga, J. N., Karanja, H., Nyagwange, J., Tuju, J., et al. (2022) · medRxiv · doi:10.1101/2022.03.03.22271860
COVID-19 mortality rates in South America related to environmental factors
Rizzo, L. V., Urrutia‐Pereira, M., Chong‐Neto, H. J., Rosário, N. E., Badellino, H., LLosa, O. M. C., Larco, J. I., Calvo, M. A., & Solé, D. (2022) · International Journal of Environmental Studies · doi:10.1080/00207233.2022.2052536
RELAÇÃO ESTRUTURA-ATIVIDADE DE FÁRMACOS ANTI-HIV DISPONIBILIZADOS PELO SISTEMA ÚNICO DE SAÚDE (SUS)
de Lira, M. F., de Melo, B. M. T., de Oliveira, L. L., Bezerra, C. D. O., Coutinho, F. N., & de Faria, A. R. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.00000107
DESAFIOS DO VÍRUS DA DENGUE NO MOSQUITO VETOR
Gonçalves, G. G. A., Feitosa, A. P. S., Brayner, F. A., & Alves, L. C. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.00000103
UMA BREVE ABORDAGEM DE LECTINA COM ATIVIDADE ANTI-SARS-CoV-2/COVID-19
Cintra, A. J. L., Torres‐León, C., Neves, J. L., & Correia, M. T. D. S. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.0000097
TERAPIAS ANTIVIRAIS: DA VACINA A NOVAS ABORDAGENS TERAPÊUTICAS
de Araújo, A. J. M., Bandeira, R. C. D. S., de Mélo, S. G. R., Calado, C. M. S. D. S., & Barbosa, A. V. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.00000109
Leung, C., Khong, K.-W., Chan, K., Lacerda, M., & Frank, C. H. M. (2022) · Pediatric Research · doi:10.1038/s41390-022-02046-3
da Costa, L. A. G., de Souza, C. G., Ferreira, A. S., de Araújo, L. V., Souza, A. T. M., & Neto, P. J. R. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.00000111
Bernardo, R. N., Aguiar, M. A. M. D. S., Ferreira, A. L., & dos Santos, K. M. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.00000100
COVID-19: IMPORTÂNCIA E AVANÇOS NO DIAGNÓSTICO DA DOENÇA
da Rosa, M. M., Pereira, M. C., Cunha, E. G. C., Albuquerque, A. P. D. B., de Oliveira, P. S. S., Carvalho, L. V. D. N., Tavares, L. B., Costa, N. T. C., de Paula, S. K. S., de Carvalho, V. M. F., et al. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.0000094
ARBOVIROSES: ASPECTOS VIRAIS, ECOLÓGICOS, CLÍNICOS E EPIDEMIOLÓGICOS
de Oliveira, M. E. D. S. P., de Lima, M. V. D. S. A., de Assunção, M. A. S., & LIMA, V. K. D. A. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.00000102
CHIKUNGUNYA: DA EPIDEMIOLOGIA AO DESENVOLVIMENTO DE VACINAS
Purificação, A., Azevedo, E. D. A. N., Lins, R. D., & Viana, I. F. T. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.00000105
FATORES DE VIRULÊNCIA VIRAIS NA COVID-19
Farias, P. C. S., da Rocha, D. A. M., Feitosa, A. P. S., Alves, L. C., & Brayner, F. A. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.0000096
Caliari, V. D. A., Muniz, D. D. M., Cavalcanti, J. V. C., Saraiva, P. R. B. D. C., Arruda, A. T. C., Melo, J. V. A. S. N. D., Arruda, A. G. T. C., & Neto, J. R. D. E. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.00000108
CARACTERÍSTICAS CLÍNICAS DA COVID-19
da Rosa, M. M., Pereira, M. C., Pessoa-e-Silva, R., Sá, J. L. F., Silva, R. C., Mendonça, A. C. S., Lima, C. A. D. O., Ferreira, M. D. A., Rego, M. J. B. M., & Pitta, M. G. D. R. (2022) · Latin American Publicações eBooks · doi:10.47174/lap2020.ed.0000095
(2021) · Microbiology Australia · doi:10.1071/mav42n1
Features of the humoral response to immunization "Gam-COVID-Vac" and in patients with COVID-19
Akinshina, Y. A., Mardanly, S. G., Ротанов, С. В., Pomazanov, V. V., Kiseleva, V. A., & Ermolaev, I. I. (2022) · Russian Clinical Laboratory Diagnostics · doi:10.51620/0869-2084-2022-67-4-227-233
Araujo, S., Cannon, M., Schmidt-Sane, M. M., Shankland, A., Snijder, M., & Wu, Y.-C. (2021) · OpenDocs (Institute of Development Studies) · doi:10.19088/sshap.2021.020
COVID-19 Mortality in Brazil, 2020-21: Consequences of the pandemic inadequate managementPreprint
Szwarcwald, C. L., Boccolini, C. S., de Almeida, W. D. S., Filho, A. M. S., & Malta, D. C. (2022) · Research Square · doi:10.21203/rs.3.rs-1678072/v2
An overview of Dentistry during and after the COVID-19 pandemic period in Brazil
Martins, C. M., Santinoni, C. D. S., de Moraes, L. D. S., Catelan, A., Monteiro, D. R., Mori, G. G., & Batista, V. E. D. S. (2022) · Research Society and Development · doi:10.33448/rsd-v11i3.23419
de Sá, E. B., Vieira, F. S., Servo, L. M. S., Benevides, R. P. D. S. E., Paulsen, S. S., & Piola, S. F. (2022) · doi:10.38116/bps29/saude
Muner, K. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.42.2021.tde-21012022-183500
Sabba, A., Pontoni, G., Santangelo, M., Rachedi, N., D’Ercole, M., Marseglia, B., Fusaro, M., & Fontana, C. (2022) · Research Square · doi:10.21203/rs.3.rs-2324373/v1
Bauer, M. S., Gruber, S., Hausch, A., Melo, M. C. R., Gomes, P. D. S. F. C., Nicolaus, T., Milles, L. F., Gaub, H. E., Bernardi, R. C., & Lipfert, J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.06.522349
COVID-19 infection rate and time spent at home: analysis of the beginning of the pandemic
Soares, V. N., Yoshida, H. M., Leme, D. E. D. C., Sampaio, R. A. C., Rufino, G. D. O., & Fernandes, P. T. (2022) · Revista de Epidemiologia e Controle de Infecção · doi:10.17058/reci.v12i2.16290
“In 2020, approximately 70% of the population had been exposed to SARS-CoV-2.(23) Between May and December 2020, COVID-19 infection and mortality rates remained low in Manaus,(22) suggesting collective immunity.”
BackgroundNurses' Covid-19 Vaccine Hesitancy: A Qualitative Study
Çatıker, A., Özdi̇l, K., Büyüksoy, G. D. B., & Öztürk, G. K. (2023) · MIDDLE BLACK SEA JOURNAL OF HEALTH SCIENCE · doi:10.19127/mbsjohs.1210520
Kataria, A. R., Kataria, P. R., & Suryawanshi, P. B. (2023) · International Journal of Community Medicine and Public Health · doi:10.18203/2394-6040.ijcmph20231041
SARS COV-2 is constantly mutating: A never-ending surge causing threat to mankind
Gupta, A., Gupta, G., Ansari, N., & Agarwal, L. (2023) · Cardiometry · doi:10.18137/cardiometry.2022.25.13691374
Análise genômica de SARS-CoV-2 na cidade de São Caetano do Sul, São Paulo, Brasil
Sales, F. C. D. S. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2023.tde-02082023-153216
Role of cellular fatty acids in combating the corona virus
Saxena, A., & Tiwari, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95582-9.00010-3
Sabba, A., Pontoni, G., Santangelo, M., Rachedi, N., D’Ercole, M., Marseglia, B., Fusaro, M., Bignami, E. G., & Fontana, C. (2023) · Journal of Anesthesia Analgesia and Critical Care · doi:10.1186/s44158-023-00114-6
“Illness progression was more common in patients with baseline-associated disease, especially in patients who presented arterial hypertension and diabetes mellitus [7].”
BackgroundSARS-CoV-2 lineage-specific disease symptoms and disease severity in São Caetano do Sul city, BrazilPreprint
Sales, F. C. D. S., Junior, C. A. P., Abade, L., Buss, L., Cândido, D. D. S., Claro, I. M., Moreira, F. R. R., Manuli, E. R., Capuani, L., da Silva, C. A. M., et al. (2023) · medRxiv · doi:10.1101/2023.10.19.23297252
Self-citationInchauste, L., Nurtop, E., Machicado, L. B., Roth, Y. L., Gonzales, S. L., Herrera, M. L., Villafan, K. M., Mamani, P. M., Espinoza, M. R., Suarez, J. C. P., et al. (2025) · eLife · doi:10.7554/elife.94475.3
Notable variants of SARS COV 2 Virus - A Mini-Review
Lawani-Luwaji, E. U., Alade, T., & John, B. U. (2023) · African Journal of Biology and Medical Research · doi:10.52589/ajbmr-eo2rwpkp
Madinga, J. N., Kingebeni, P. M., Nkuba, A.-J., Baketana, L., Matungulu, É., Vanlerberghe, V., Lupola, P. M., Seghers, C.-A., Smekens, T., Ariën, K. K., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3710665/v1
Inchauste, L., Nurtop, E., Machicado, L. B., Roth, Y. L., Gonzales, S. L., Herrera, M. L., Villafan, K. M., Mamani, P. M., Espinoza, M. R., Suarez, J. C. P., et al. (2024) · eLife · doi:10.7554/elife.94475.1
Inchauste, L., Nurtop, E., Machicado, L. B., Roth, Y. L., Gonzales, S. L., Herrera, M. L., Villafan, K. M., Mamani, P. M., Espinoza, M. R., Suarez, J. C. P., et al. (2024) · eLife · doi:10.7554/elife.94475
“%) after the first wave ( Álvarez-Antonio et al., 2021 ; Buss et al., 2021 ).”
InfluentialLata, S., & Akif, M. (2024) · Molecular Systems Design & Engineering · doi:10.1039/d3me00193h
Li, X., Wu, P., Bao, D., Guo, Z., Jiang, H., Sui, Y., Bian, W., Wang, S., Zhang, F., Wu, J., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4254091/v1
SARS-CoV-2 epidemiology, kinetics, and evolution: a narrative reviewPreprint
Alizon, S., & Sofonea, M. T. (2024) · doi:10.31219/osf.io/etv85
Ferreira, A. M., Silva, L. C. O.-D., Cardoso, C. S., Oliveira, C. D. L., Brito, B. O. D. F., Bierrenbach, A. L., Santos, A. C. D. J., Cruz, D. S., Leite, S. F., Jesus, A. B., et al. (2024) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2024.102745
Finch, E., Nilles, E. J., Paulino, C. T., Skewes-Ramm, R., Lau, C. L., Lowe, R., & Kucharski, A. J. (2024) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2024.100860 · Cited by 5
Silva, T. C., Boaventura, V. S., Pearce, N. E., & Barral‐Netto, M. (2024) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2024.107241 · Cited by 1
Self-citationInchauste, L., Nurtop, E., Machicado, L. B., Roth, Y. L., Gonzales, S. L., Herrera, M. L., Villafan, K. M., Mamani, P. M., Espinoza, M. R., Suarez, J. C. P., et al. (2025) · eLife · doi:10.7554/elife.94475.2
Braeye, T., Abrams, S., & Hens, N. (2025) · medRxiv · doi:10.1101/2025.06.29.25330529
Braeye, T., Pauw, R. D., Geebelen, L., Abrams, S., Desombere, I., Hens, N., Hammami, N., Roelants, M., & Herzog, S. A. (2025) · medRxiv · doi:10.1101/2025.07.02.25330709
Parra, G., Lessa, F. C., Campelo, E., Ramos, T. C. A., Vieira, A. R., Lalwani, P. J., Nichiata, L. Y. I., Silva-Flannery, L. M., Siza, C. R., Lima, K. J. V., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf339 · Cited by 1
“…in our study is notably lower than what was observed in Manaus just a few months prior (76% in the general population in the month of October 2020 vs 2% among our cohort participants) [40], possibly due to the short follow-up period and high immunity from prior infection or vaccination at baseline.”
Backes, M. T. S., Knoblauch, M. V. D. A., & Will, S. F. (2025) · Revista de estudios brasileños · doi:10.14201/reb20241123185200
Additional file 1 of Reinfection by the SARS-CoV-2 Gamma variant in blood donors in Manaus, Brazil
Junior, C. A. P., Buss, L., Buccheri, R., Abrahim, C. M. M., Salomon, T., Crispim, M. A. E., Oikawa, M. K., Grebe, E., da Costa, A. G., Fraiji, N. A., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19128607
Self-citationDiagnostic performance of lateral flow immunoassays for COVID-19 antibodies in Peruvian populationPreprint
Calderon-Flores, R., Caceres-Cardenas, G., Alí, K., Vos, M. D., Emperador, D., Cáceres, T., Eca, A., Villa, L., Albertini, A., Sacks, J. A., et al. (2023) · medRxiv · doi:10.1101/2023.01.13.23284518
Duong, S., Burtniak, J., Gretchen, A., Mai, A., Klassen, P., Wei, Y., Loeppky, C., Shaw, S. Y., Bullard, J., Caeseele, P. G. V., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24751292
SARS-CoV-2 lineage-specific disease symptoms and disease severity in a city in southeastern Brazil
Sales, F. C. D. S., Junior, C. A. P., Abade, L., Buss, L., Cândido, D. D. S., Claro, I. M., Moreira, F. R. R., Manuli, E. R., Capuani, L., da Silva, C. A. M., et al. (2026) · Revista do Instituto de Medicina Tropical de São Paulo · doi:10.1590/s1678-9946202668007
“First detected in Manaus, a region that achieved a high infection rate during the first wave 6 , 7 , the Gamma VOC quickly spread to all Brazilian cities dramatically increasing COVID-19 deaths.”
Self-citationBraeye, T., Pauw, R. D., Geebelen, L., Abrams, S. A., Desombere, I., Hens, N., Hammami, N., Roelants, M., Muylaert, A., & Herzog, S. A. (2026) · Archives of Public Health · doi:10.1186/s13690-026-01860-z
“Others included single Weibull distributions [25, 67, 68] or constant exponential rates [69–71].”
InfluentialRakotondramanga, J. M. (2023) · theses.fr (ABES) · doi:10.70675/aae0cc9az3b0fz4ccdzb05az583a89448b7d
Seroepidemiology of emerging viruses in Bolivia
Jordan, L. I. (2023) · theses.fr (ABES) · doi:10.70675/1070f335z49aaz4d85zb796z713dd35bc6fc
Owusu‐Boaitey, N., Meyer, M. J., Herrera, D., Böttcher, L., Lukz, M., Cook, S., Stoto, . A., & Kraemer, J. D. (2026) · medRxiv · doi:10.64898/2026.06.09.26355264
Inchauste, L., de Lamballerie, X. N., Priet, S., Cayuba, M. G., Adrian, J. C., Rodríguez, D. E., Gutierrez, R. Q., Alami, S., Aronoff, J. E., Buetow, K. H., et al. (2026) · Social Science & Medicine · doi:10.1016/j.socscimed.2026.119493
Martins, A., Santos, M. F. B., Nascimento, J., Chui, F. M. D. S., Rodrigues, M., Bastos, T. X., Lemos, S., Honorato, E., Cortez, M., Xavier, M. S., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0351566
“At baseline (D0), both groups exhibited comparable rates of seropositivity, indicating a high prevalence of prior exposure to SARS-CoV-2 in the study population, which is consistent with findings from surveys conducted in Manaus [28,29].”
Duncan, J. P., Jackson, M. D., Cooper, C. J., Anzinger, J. J., Ehikhametalor, K., Facey, K.-A., Cloherty, G., & Tulloch-Reid, M. K. (2026) · Health Science Reports · doi:10.1002/hsr2.72761
Rodrigues, M. G. D. A., Balieiro, P. C. D. S., Silva-Neto, A. V., Val, F., Endo, P. T., & Sampaio, V. D. S. (2026) · International Journal of Epidemiology · doi:10.1093/ije/dyag190
Paolino, B. M., Maestá, I., Paolino, M. N. F., Ono, L. M., Berkowitz, R. S., & Horowitz, N. S. (2026) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2026.102234
“Notably, this restructuring coincided with the COVID-19 pandemic (Buss et al., 2021) and severe logistical challenges, including record-breaking Amazonian river floods in 2021, which disrupted healthcare delivery.”
Queiroz, B. L., de Lima, E. E. C., Díaz, J. P. M., Gonzaga, M. R., Freire, F. H. M. D. A., & Baptista, E. A. (2026) · Spatial Demography · doi:10.1007/s40980-026-00174-6
“…elevated all-cause mortality relative to other Brazilian regions, reflecting long-standing structural disadvantages, including lower health infrastructure density, geographic isolation, and a higher burden of infectious and parasitic diseases (Buss et al., 2021; Orellana et al., 2022a, b ).”
Martin, D. P., Weaver, S., Tegally, H., San, E. J., Shank, S. D., Wilkinson, E., Lucaci, A. G., Giandhari, J., Naidoo, S., Pillay, Y., et al. (2021) · doi:10.1101/2021.02.23.21252268 · Cited by 291
Metadata
- Authors
- Buss, L. F., Prete, C. A., Abrahim, C. M. M., Mendrone, A., Salomon, T., de Almeida-Neto, C., França, R. F. O., Belotti, M. C., Carvalho, M. P. S. S., Costa, A. G., Crispim, M. A. E., Ferreira, S. C., Fraiji, N. A., Gurzenda, S., Whittaker, C., Kamaura, L. T., Takecian, P. L., da Silva Peixoto, P., Oikawa, M. K., Nishiya, A. S., Rocha, V., Salles, N. A., de Souza Santos, A. A., da Silva, M. A., Custer, B., Parag, K. V., Barral-Netto, M., Kraemer, M. U. G., Pereira, R. H. M., Pybus, O. G., Busch, M. P., Castro, M. C., Dye, C., Nascimento, V. H., Faria, N. R., & Sabino, E. C.
- Affiliations
- Universidade de São Paulo (BR)
- Departamento de Engenharia de Sistemas Eletrônicos, Escola Politécnica da Universidade de São Paulo, São Paulo, Brazil.
- Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas (BR)
- Faculdade de Ciências Médicas de Minas Gerais (BR)
- Fundação Pró-Sangue–Hemocentro de São Paulo, São Paulo, Brazil.
- Department of Virology and Experimental Therapy, Institute Aggeu Magalhaes, Oswaldo Cruz Foundation, Recife, Brazil.
- Fundação Hospitalar de Hematologia e Hemoterapia do Amazonas, Manaus, Brazil.
- Harvard University (US)
- Imperial College London (GB)
- Institute of Mathematics and Statistics, University of São Paulo, São Paulo, Brazil.
- Center of Mathematics, Computing and Cognition–Universidade Federal do ABC, São Paulo, Brazil.
- Fundação Pró-Sangue Hemocentro de São Paulo (BR)
- Oxford School of Global and Area Studies, Latin American Centre, University of Oxford, Oxford, UK.
- University of California, San Francisco (US)
- Instituto Gonçalo Moniz–Fundação Oswaldo Cruz (Fiocruz), Salvador, Brazil.
- University of Oxford (GB)
- Institute of Applied Economic Research (BR)
- Departamento de Molestias Infecciosas e Parasitarias and Instituto de Medicina Tropical da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
- Corresponding author
- Buss, Lewis F.
- Abrahim, Claudia M. M.
- Mendrone, Alfredo
- Salomon, Tassila
- Faria, Nuno R.
- ORCID
- Buss, Lewis F.
- Prete, Carlos A.
- Abrahim, Claudia M. M.
- Mendrone, Alfredo
- Salomon, Tassila
- de Almeida-Neto, Cesar
- França, Rafael F. O.
- Belotti, Maria C.
- Carvalho, Maria P. S. S.
- Costa, Allyson G.
- Crispim, Myuki A. E.
- Ferreira, Suzete C.
- Fraiji, Nelson A.
- Gurzenda, Susie
- Whittaker, Charles
- Kamaura, Leonardo T.
- Takecian, Pedro L.
- da Silva Peixoto, Pedro
- Oikawa, Marcio K.
- Nishiya, Anna S.
- Rocha, Vanderson
- Salles, Nanci A.
- de Souza Santos, Andreza Aruska
- da Silva, Martirene A.
- Custer, Brian
- Parag, Kris V.
- Barral-Netto, Manoel
- Kraemer, Moritz U. G.
- Pereira, Rafael H. M.
- Pybus, Oliver G.
- Busch, Michael P.
- Castro, Márcia C.
- Dye, Christopher
- Nascimento, Vítor H.
- Faria, Nuno R.
- Sabino, Ester C.
- Venue
- Science
- Published
- 2021-01-15
- Volume
- 371
- Issue
- 6526
- Pages
- 288-292
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7857406
- OpenAlex
- W3112547455
- Cited by
- 488
- References
- 47
- Citations by year
- 2026: 10 · 2025: 17 · 2024: 29 · 2023: 56 · 2022: 119 · 2021: 240
- FWCI
- 35.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- Medical Research Council (MR/S0195/1)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (18/14389-0)
- Itau Unibanco Todos pela Saude
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, COVID-19 pandemic, attack rate, seroprevalence, immunoglobulin G antibodies, Manaus, Amazonas, antibody waning, blood donors, epidemic size estimation
- MeSH terms
- COVID-19, SARS-CoV-2, Adolescent, Adult, Aged, Antibodies, Viral, Blood Donors, Brazil, Female, Humans, Immunoglobulin G, Male, Middle Aged, Seroepidemiologic Studies, Young Adult, Epidemics, Epidemiological Monitoring
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.